Pathology of durable stable disease in melanoma patients treated with ipilimumab, nivolumab, or ipilimumab, and nivolumab combination therapy.

Authors

null

Elizabeth Iannotti Buchbinder

Dana-Farber Cancer Institute, Boston, MA

Elizabeth Iannotti Buchbinder , Kathleen L. Pfaff , Michael P. Manos , Olivia Ouyang , Patrick Alexander Ott , Scott J. Rodig , F. Stephen Hodi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 9567)

DOI

10.1200/JCO.2021.39.15_suppl.9567

Abstract #

9567

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Minke W. Lucas

First Author: Jason J. Luke

Poster

2018 ASCO Annual Meeting

Activity of targeted therapy after failure of first-line immunotherapy in BRAF-mutant metastatic melanoma.

Activity of targeted therapy after failure of first-line immunotherapy in BRAF-mutant metastatic melanoma.

First Author: Cathy Yi Xia